Printer Friendly
The Free Library
19,585,946 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Amgen Acquisition of Kinetix Closes.


Business Editors

THOUSAND OAKS Thousand Oaks, residential city (1990 pop. 104,352), Ventura co., S Calif., in a farm area; inc. 1964. Avocados, citrus, vegetables, strawberries, and nursery products are grown. , Calif.--(BUSINESS WIRE)--Dec. 14, 2000

Amgen (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:AMGN) today announced that it has completed its previously-announced acquisition of Kinetix Pharmaceuticals, Inc., an innovator in the discovery of small molecule drugs in the field of protein kinase protein kinase /pro·tein ki·nase/ (pro´ten ki´nas) an enzyme that catalyzes the phosphorylation of serine, threonine, or tyrosine groups in enzymes or other proteins, using ATP as a phosphate donor.  inhibition.

"This acquisition and subsequent integration are significant steps in developing our small molecule capabilities, which is a key initiative in realizing our aspiration of becoming the best human therapeutics company in the world," said Dennis Fenton, Ph.D., Executive Vice President.

Amgen's acquisition of Kinetix is expected to provide an important building block in Amgen's small molecule drug discovery program. It will provide Amgen with a discovery platform engine that can rapidly produce and optimize high quality lead compounds.

Amgen is a global biotechnology company that discovers, develops, manufactures and markets cost-effective human therapeutics based on advances in cellular and molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller .

EDITOR'S NOTE Editor's Note (foaled in 1993 in Kentucky) is an American thoroughbred Stallion racehorse. He was sired by 1992 U.S. Champion 2 YO Colt Forty Niner, who in turn was a son of Champion sire Mr. Prospector and out of the mare, Beware Of The Cat.

Trained by D.
: An electronic version of this news release may be accessed via our web site at www.Amgen.com. Visit the Corporate Center and click on Amgen News. Journalists and media representatives may sign up to receive all news releases electronically at time of announcement by filling out a short form in the Amgen News section of the web site.
COPYRIGHT 2000 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Dec 14, 2000
Words:205
Previous Article:EARTH Establishes Enhanced Production Facility in Canada.
Next Article:Caribgold Acquires 118-Claim Property Near Noranda's Matagami Base Metal Discovery.



Related Articles
AMGEN'S PUNISHMENT CONTINUES IMMUNEX ACQUISITION SAPS INVESTOR SUPPORT.
AMGEN TO PAY $16 BILLION FOR FELLOW 'GOLIATH'.
AMGEN TO BUY BOSTON FIRM; TOUTS NEW DRUG.
AMGEN MAY GO SHOPPING FOR GROWTH, PRESIDENT SAYS.
AMGEN STOCK DECLINES ON DOWNGRADE.
IN BRIEF.
AMGEN DEAL GAINS OK SHAREHOLDERS APPROVE IMMUNEX ACQUISITION.
FTC PUTS AMGEN DEAL CLOSER TO REAL MAJOR DRUG MERGER LOOMS.
PARTNERSHIP RUMORED FOR ABGENIX, AMGEN.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles